The Ohio State University, 2121 Kenney Road, Columbus, OH, 43210, USA.
Curr Hematol Malig Rep. 2024 Apr;19(2):45-55. doi: 10.1007/s11899-023-00721-8. Epub 2024 Jan 9.
This review presents recently published clinical trial data and ongoing investigations regarding the treatment of Richter's transformation (RT).
Recently, numerous approaches have been investigated for the treatment of RT including: traditional chemoimmunotherapy regimens combined with targeted agents such as BTKi and BCL2i; immunotherapy combined with targeted agents; non-covalent BTKis; bispecific T cell engagers; and CART therapy. In addition, various novel targeted agents are currently being studied for the treatment of RT in phase 1 and 2 clinical trials. Standard of care treatment with chemoimmunotherapy for RT has limited efficacy in achieving durable remissions. Here, we review recent data on the use of combination treatments and targeted agents in RT. Although some progress has been made in the investigation to optimize treatment of RT, further study is needed to evaluate long term outcomes of recently published trials and test efficacy of upcoming novel agents.
本综述介绍了近期发表的临床试验数据和正在进行的有关里希特转化（RT）治疗的研究。
最近，已经研究了许多方法来治疗 RT，包括：传统的化疗免疫治疗方案联合靶向药物，如 BTKi 和 BCL2i；免疫治疗联合靶向药物；非共价 BTKis；双特异性 T 细胞衔接器；和 CART 治疗。此外，目前正在进行各种新型靶向药物的 1 期和 2 期临床试验，以治疗 RT。针对 RT 的标准化疗免疫治疗方案在实现持久缓解方面疗效有限。在这里，我们回顾了 RT 中联合治疗和靶向药物使用的最新数据。虽然在优化 RT 治疗的研究方面取得了一些进展，但仍需要进一步研究来评估近期发表试验的长期结果，并测试即将推出的新型药物的疗效。
